Parkman Healthcare Partners LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001777015
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 100 positions · Total reported value $1.05B · Top-10 concentration 32.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 68.0% · 26 new · 31 cut · 13 exited
Active Share (vs S&P 500): 97.4% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -2.8% · vs SPY -4.9% · Prev Value $976.83M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -1.8% · vs SPY -4.0% · Latest Value $1.11B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2025 13F filing, Parkman Healthcare Partners LLC disclosed 100 equity positions with a combined reported value of $1.05B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 32.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were BSX ($47.73M), PODD ($40.04M), DXCM ($38.99M). By sector, the heaviest allocations are Health Care 72.9%, Industrials 7.7%. Versus the prior quarter, allocation shifted toward Industrials (+4.9pp) and away from Technology (-1.2pp), Health Care (-3.9pp).
Versus the prior quarter, Parkman Healthcare Partners LLC opened 26 new positions, trimmed 31 and fully exited 13, a turnover rate of 68.0% of positions. The portfolio's overlap with the prior quarter was 72% of names.
The largest new positions opened in Q4 2025 were MASI ($26.01M), EYPT ($19.88M), WAT ($15.91M).
Of the 13 positions fully exited versus the prior quarter, the largest were QQQ ($48.03M), UTHR ($9.22M), INCY ($8.52M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
Fully Exited (vs previous quarter)
- QQQ INVESCO QQQ TR · prev qtr: $48.03M
- UTHR UNITED THERAPEUTICS CORP DEL · prev qtr: $9.22M
- INCY INCYTE CORP · prev qtr: $8.52M
- ASND ASCENDIS PHARMA A/S · prev qtr: $8.02M
- LLY ELI LILLY & CO · prev qtr: $7.63M · history
- BMRN BIOMARIN PHARMACEUTICAL INC · prev qtr: $6.82M
- OM OUTSET MED INC · prev qtr: $6.42M
- ABVX ABIVAX SA · prev qtr: $4.69M
Insider Transactions (Form 4)
Latest Parkman Healthcare Partners LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Parkman Healthcare Partners LLC, based in Stamford, CT, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 77 positions worth $976.83M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: STAMFORD, CT, United States
- SEC registration: 801-114849 (status: Approved), registered 2019-03-15
- Regulatory AUM (Form ADV): $1.74B as of 2026-03-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
Portfolio Structure
- 77 positions · $976.83M reported value (Q2 2026)
- Top 10 holdings = 33.5% of reported value
- Largest position: MBX (MBX BIOSCIENCES INC COM) at 4.5%
- Average position size: $12.69M
Sector Tilt
- Health Care 92.1%
- Consumer Staples 4.1%
- Industrials 3.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 18 new, 25 added, 30 reduced, 31 exited
- 4 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
500.53K | $47.73M | 4.54% | Add | |
| 2 |
|
140.86K | $40.04M | 3.81% | Add | |
| 3 |
|
587.48K | $38.99M | 3.71% | Add | |
| 4 |
|
105.47K | $37.07M | 3.53% | Add | |
| 5 |
|
450.21K | $35.73M | 3.40% | Add | |
| 6 |
|
36.35K | $29.82M | 2.84% | Add | |
| 7 |
|
1.77M | $28.56M | 2.72% | Add | |
| 8 |
|
885.64K | $27.93M | 2.66% | Add | |
| 9 |
|
665.21K | $27.44M | 2.61% | Reduce | |
| 10 |
|
200.00K | $26.01M | 2.48% | New | |
| 11 |
|
410.91K | $25.28M | 2.41% | Add | |
| 12 |
|
620.88K | $25.08M | 2.39% | Reduce | |
| 13 |
|
788.08K | $24.52M | 2.33% | Reduce | |
| 14 |
|
968.60K | $23.08M | 2.20% | Add | |
| 15 |
|
834.56K | $22.66M | 2.16% | Reduce | |
| 16 |
|
494.35K | $22.23M | 2.12% | Reduce | |
| 17 |
|
1.49M | $21.18M | 2.02% | Reduce | |
| 18 |
|
1.09M | $19.88M | 1.89% | New | |
| 19 |
|
47.70K | $18.97M | 1.81% | Reduce | |
| 20 |
|
114.71K | $16.27M | 1.55% | Reduce | |
| 21 |
|
41.90K | $15.91M | 1.51% | New | |
| 22 |
|
10.99K | $15.32M | 1.46% | New | |
| 23 |
|
410.25K | $14.89M | 1.42% | Reduce | |
| 24 |
|
430.15K | $13.65M | 1.30% | Add | |
| 25 |
|
100.00K | $13.61M | 1.29% | New | |
| 26 |
|
151.05K | $13.58M | 1.29% | Reduce | |
| 27 |
|
58.89K | $13.48M | 1.28% | Reduce | |
| 28 |
|
1.69M | $13.28M | 1.26% | Reduce | |
| 29 |
|
150.99K | $12.87M | 1.23% | Reduce | |
| 30 |
|
160.18K | $12.17M | 1.16% | Reduce | |
| 31 |
|
369.02K | $12.09M | 1.15% | Add | |
| 32 |
|
574.02K | $12.06M | 1.15% | Reduce | |
| 33 |
|
60.51K | $12.03M | 1.15% | Reduce | |
| 34 |
|
118.71K | $11.94M | 1.14% | Reduce | |
| 35 |
|
145.00K | $11.45M | 1.09% | New | |
| 36 |
|
427.69K | $10.61M | 1.01% | Reduce | |
| 37 |
|
31.88K | $10.52M | 1.00% | New | |
| 38 |
|
125.33K | $10.27M | 0.98% | Reduce | |
| 39 |
|
218.67K | $9.97M | 0.95% | Reduce | |
| 40 |
|
130.07K | $9.82M | 0.94% | Add | |
| 41 |
|
209.27K | $8.67M | 0.82% | Add | |
| 42 |
|
249.36K | $8.48M | 0.81% | Reduce | |
| 43 |
|
128.11K | $8.35M | 0.80% | Reduce | |
| 44 |
|
250.32K | $8.19M | 0.78% | Reduce | |
| 45 |
|
35.23K | $7.94M | 0.76% | Add | |
| 46 |
|
374.38K | $7.38M | 0.70% | Reduce | |
| 47 |
|
162.28K | $7.19M | 0.68% | Reduce | |
| 48 |
|
900.06K | $7.02M | 0.67% | Reduce | |
| 49 |
|
154.18K | $6.91M | 0.66% | Reduce | |
| 50 |
|
538.65K | $6.60M | 0.63% | Add | |
FAQ
What did Parkman Healthcare Partners LLC buy in 2025-Q4?
In its 2025-Q4 13F filing, Parkman Healthcare Partners LLC reported 100 equity positions worth $1.05B in aggregate; its largest disclosed positions were BSX ($47.73M), PODD ($40.04M), DXCM ($38.99M).
How large is Parkman Healthcare Partners LLC's portfolio?
Parkman Healthcare Partners LLC reported $1.05B of long equity holdings across 100 positions as of 2025-Q4. Top-10 holdings account for 32.3% of reported value.
What is Parkman Healthcare Partners LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.